Oncolytics Biotech Starts Patient Treatment in UK Phase I Cancer Trial Investigating Systemic Delivery of REOLYSIN(R)
Calgary - Oncolytics Biotech Inc. ("Oncolytics") announced that it has started patient treatment in its UK Phase I clinical trial investigating the systemic delivery of REOLYSIN(R) as a treatment for patients with advanced or metastatic solid tumours.
This clinical trial is an open-label, dose-escalation Phase I study in which REOLYSIN(R) will be administered intravenously to patients diagnosed with advanced or metastatic solid tumours that are refractory to standard therapy (have not responded) or for which no curative standard therapy exists. The primary objective of the study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and safety profile of REOLYSIN(R). Secondary objectives include the evaluation of viral replication, immune response to the virus and any evidence of antitumour activity. The enrolment in this study is expected to be up to forty evaluable patients and will depend upon the number of dose levels tested. The principal investigator for the study is Dr. J. de Bono of the Royal Marsden Hospital.
Other news from the department science
